机器人辅助结肠切除术在I-III期结肠癌中与改善的围术期结局和有利生存相关:一项全国性重叠加权分析
该多中心回顾性队列研究基于日本MDV数据库分析43,540例I-III期结肠癌患者,比较开腹、腹腔镜与机器人辅助结肠切除术的短期和生存结局,经重叠加权后有效样本34,236例。机器人组术后并发症、输血、30天和90天死亡率最低,住院时间最短、费用最低,3年OS和RFS均优于腹腔镜和开腹组。
要点
- 机器人辅助结肠切除术与最低的术后并发症、输血率和30/90天死亡率相关。
- 机器人组住院时间最短、住院费用最低。
- 机器人组3年OS 95%、RFS 94%,优于腹腔镜和开腹组。
核心结论
- 与腹腔镜和开腹结肠切除术相比,机器人辅助结肠切除术在I-III期结肠癌中与有利的短期结局和生存曲线相关。
- 需要更长期随访的前瞻性研究来明确其生存肿瘤学影响。
研究设计与样本
- 多中心回顾性队列研究,使用日本Medical Data Vision数据库分析43,540例临床I-III期结肠癌患者,手术时间2022年4月至2025年9月。
- 采用重叠加权调整基线差异,有效样本量为34,236例。
主要发现
- 重叠加权后,机器人组3,694例,腹腔镜组25,975例,开腹组4,567例。
- 机器人组术后并发症、术中输血、30天和90天死亡率最低,住院时间最短,住院费用最低。
- 3年OS率在机器人组、腹腔镜组和开腹组分别为95%、94%和90%(p < 0.001)。
- 3年RFS率在机器人组、腹腔镜组和开腹组分别为94%、92%和88%。
临床怎么用
- 在I-III期结肠癌择期手术中,机器人辅助结肠切除术可作为与腹腔镜和开腹手术相比短期结局更优的选择。
- 机器人辅助结肠切除术与更低的术后并发症、输血率和30/90天死亡率相关,并缩短住院时间、降低住院费用。
局限性
- 为回顾性队列研究,可能存在未测量混杂。
- 随访时间有限,生存肿瘤学影响需更长期前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robot-assisted colectomy has been increasingly adopted for colon cancer because of its technical advantages; however, evidence regarding its short- and survival oncological outcomes remains limited. The aim of this study was to compare short- and survival outcomes among open, laparoscopic, and robot-assisted colectomy (OC, LC, and RAC) for stage I-III colon cancer using a large real-world database. METHODS: This multicenter retrospective cohort study analyzed 43,540 patients with clinical stage I-III colon cancer who underwent colectomy between April 2022 and September 2025 using the Japanese Medical Data Vision database. To adjust for baseline differences across surgical approaches, overlap weighting was applied, yielding an effective sample size of 34,236 patients. Primary outcomes included postoperative complications, perioperative mortality, length of hospital stay, and hospitalization costs. Secondary outcomes were overall survival (OS) and recurrence-free survival (RFS). RESULTS: After overlap weighting, 3,694 patients underwent RAC, 25,975 underwent LC, and 4,567 underwent OC. The RAC group demonstrated the lowest rates of postoperative complications, intraoperative blood transfusion, and 30- and 90-day mortality, as well as the shortest hospital stay and lowest hospitalization costs. The 3-year OS rates were 95, 94, and 90% in the RAC, LC, and OC groups, respectively (p < 0.001), with corresponding RFS rates of 94, 92, and 88%. CONCLUSIONS: Compared with LC and OC, RAC for stage I-III colon cancer was associated with favorable short-term outcomes and survival profiles. Prospective studies with longer follow-up are warranted to clarify its survival oncological impact.
引用
- Yamazaki N, Hanaoka M, Yamauchi S, et al. Robot-assisted colectomy is associated with improved perioperative outcomes and favorable survival in stage I-III colon cancer: a nationwide overlap-weighted analysis. Surg Endosc. 2026. PMID: 42722913. doi:10.1007/s00464-026-13351-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。